Current salvage therapies in Hodgkin lymphoma
K Chohan, SM Ansell - Leukemia & Lymphoma, 2022 - Taylor & Francis
Hodgkin lymphoma is a B-cell malignancy with approximately 85–95% complete remission
rate following frontline therapy; however, relapsed/refractory disease occurs in roughly 10 …
rate following frontline therapy; however, relapsed/refractory disease occurs in roughly 10 …
How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation
GF Perini, T Fischer, RD Gaiolla, TB Rocha… - … , Transfusion and Cell …, 2020 - SciELO Brasil
The novel Coronavirus (CoVid-19) outbreak is now consider a world pandemic, affecting
more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease …
more than 1,300,000 people worldwide. Cancer patients are in risk for severe disease …
Лимфома Ходжкина
ЕА Демина, ГС Тумян, ТН Моисеева… - Современная …, 2020 - cyberleninka.ru
ЛИМФОМА ХОДЖКИНА – тема научной статьи по клинической медицине читайте
бесплатно текст научно-исследовательской работы в электронной библиотеке …
бесплатно текст научно-исследовательской работы в электронной библиотеке …
GDP (gemcitabine, dexamethasone, and cisplatin) is highly effective and well-tolerated for newly diagnosed stage IV and relapsed/refractory extranodal natural killer/T …
GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Ef... : Medicine GDP (Gemcitabine,
Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed …
Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed …
Rosiglitazone use and the risk of bladder cancer in patients with type 2 diabetes
Patients with diabetes have a higher incidence of bladder cancer; however, the association
between thiazolidinedione use and bladder cancer risk has been controversial. We aimed to …
between thiazolidinedione use and bladder cancer risk has been controversial. We aimed to …
Hodgkin's lymphoma
EA Demina, GS Tumyan… - Journal of Modern …, 2020 - modernonco.orscience.ru
Лимфома Ходжкина Page 1 клиническая онкология / clinical oncology 6 JOURNAL OF
MODERN ONCOLOGY 2020 | VOL. 22 | NO. 2 современная онкология 2020 | том 22 | №2 …
MODERN ONCOLOGY 2020 | VOL. 22 | NO. 2 современная онкология 2020 | том 22 | №2 …
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas
Cisplatin-containing salvage regimens followed by autologous hematopoietic stem cell
(HSC) transplantation are the current standard of care for relapsed or refractory (R/R) …
(HSC) transplantation are the current standard of care for relapsed or refractory (R/R) …
Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China
S Xie, Y Sheng, LH Chuang, J Wu - Health Economics Review, 2024 - Springer
Background Relapsed or refractory classic Hodgkin lymphoma (RRcHL) associates with
poor prognosis and heavy disease burden to patients. This study evaluated the cost …
poor prognosis and heavy disease burden to patients. This study evaluated the cost …
Gemcitabine, vinorelbine and dexamethasone: a safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma
Background Salvage regimens in relapsed/refractory Hodgkin's lymphoma (HL) differ in their
efficacy and toxicity profiles. Gemcitabine (G), vinorelbine (V) and liposomal doxorubicin …
efficacy and toxicity profiles. Gemcitabine (G), vinorelbine (V) and liposomal doxorubicin …
[HTML][HTML] Long-term outcomes of upfront concurrent chemoradiotherapy followed by P-GDP regimen in newly diagnosed early stage extranodal nasal-type NK/T cell …
F Zhu, T Liu, H Pan, Y Xiao, Q Li, X Liu, W Chen, G Wu… - Medicine, 2020 - journals.lww.com
The optimal treatment strategy of newly diagnosed stage I/II, extranodal nasal-type natural
killer/T cell lymphoma (NKTCL) remains unclear. This prospective phase II trial was …
killer/T cell lymphoma (NKTCL) remains unclear. This prospective phase II trial was …